Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia.
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia. Am J Hematol. 2022 08; 97(8):E296-E298.